Related Experiment Videos
A single-center experience with 1,378 CarboMedics mechanical valve implants.
M J Dalrymple-Hay1, R Pearce, S Dawkins
1Wessex Cardiothoracic Centre, Southampton General Hospital, United Kingdom. mdh@btinternet.com
The Annals of Thoracic Surgery
|March 29, 2000
Summary
The CarboMedics bileaflet prosthetic heart valve shows good midterm results, with a low incidence of valve-related complications and high survival rates. This analysis of clinical experience confirms its efficacy in heart valve replacement.
Area of Science:
- Cardiovascular Surgery
- Biomaterials Science
- Clinical Outcomes Research
Background:
- The CarboMedics bileaflet prosthetic heart valve was introduced in 1986.
- Clinical implantation of this valve began in March 1991.
- This study aimed to evaluate the clinical performance of the CarboMedics valve.
Purpose of the Study:
- To analyze the clinical experience with the CarboMedics bileaflet prosthetic heart valve.
- To assess the midterm outcomes of patients receiving this prosthetic valve.
- To determine the incidence of valve-related complications and survival rates.
Main Methods:
- A cohort of 1,247 patients received 1,378 CarboMedics valves between March 1991 and December 1997.
- Patient demographics included 705 men (56.5%) and 542 women (43.5%), with a mean age of 62 years.
- Follow-up was 99% complete, totaling 3,978 patient-years.
Main Results:
- Early mortality rate was 4.4%.
- Five-year survival rate was 79.2% (±1.4%).
- Five-year freedom from valve-related complications was 80.6% (±1.4%), with low linearized rates for bleeding (1.73%/pt-yr), embolism (1.76%/pt-yr), and endocarditis (0.18%/pt-yr).
Conclusions:
- The CarboMedics prosthetic heart valve demonstrates favorable midterm clinical outcomes.
- A low incidence of valve-related complications was observed.
- The valve is associated with acceptable survival and reoperation rates.